Filing Flows › GeneDx Holdings (WGS) › Q1 2026 › vs Q4 2025
GeneDx Holdings (WGS) Q1 2026 vs Q4 2025 (quarter over quarter)
GeneDx Holdings's revenue fell $18.7M (-15%) from $121M in Q4 2025 to $102M in Q1 2026. The biggest changes: Diagnostic Test −$16.0M (-14%); Other revenue −$2.7M (-74%); Self-pay patients −$11K (-4%).
GeneDx Holdings, Q1 2026: revenue $102M (+17% year over year), operating margin -56.2%, net loss $63.3M, operating cash flow −$32.4M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Patients with third-party insurance | $84.9M | $101M | −$16.1M | -16% |
| Institutional customers | $16.1M | $15.9M | $157K | +1% |
| Diagnostic Test | $101M | $117M | −$16.0M | -14% |
| Other revenue | $955K | $3.7M | −$2.7M | -74% |
| Self-pay patients | $286K | $297K | −$11K | -4% |
| Revenue | $102M | $121M | −$18.7M | -15% |
| Net loss | $63.3M | $17.7M | $45.6M | +258% |
| Costs & expenses | $166M | $139M | $26.4M | +19% |
| Operating costs | $160M | $135M | $24.5M | +18% |
| Interest & other, net | $4.9M | $4.0M | $953K | +24% |
| Income tax | $897K | −$564K | $1.5M | — |
| Cost of revenue | $34.0M | $36.7M | −$2.7M | -7% |
| Research & development | $19.8M | $24.5M | −$4.7M | -19% |
| Operating cash sources | $63.3M | $17.7M | $45.6M | +258% |
| Depreciation & amortization | $6.8M | $6.9M | −$72K | -1% |
| Share-based compensation | $9.0M | $9.8M | −$784K | -8% |
| Working capital & other | $15.1M | −$2.1M | $17.2M | — |
| Cash used in operations | $32.4M | $3.1M | $29.3M | +949% |
| Net loss absorbed | $63.3M | $17.7M | $45.6M | +258% |
Questions
How much did GeneDx Holdings's revenue grow quarter over quarter in Q1 2026?
GeneDx Holdings's revenue fell $18.7M (-15%) from $121M in Q4 2025 to $102M in Q1 2026.
What drove GeneDx Holdings's revenue change in Q1 2026?
Diagnostic Test −$16.0M (-14%); Other revenue −$2.7M (-74%); Self-pay patients −$11K (-4%).